

Betty M Tijms

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3646511/publications.pdf>

Version: 2024-02-01

79
papers

4,456
citations

159358

30
h-index

114278

63
g-index

86
all docs

86
docs citations

86
times ranked

6535
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. Neurobiology of Aging, 2013, 34, 2023-2036.	1.5	355
3	Similarity-Based Extraction of Individual Networks from Gray Matter MRI Scans. Cerebral Cortex, 2012, 22, 1530-1541.	1.6	258
4	Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain, 2016, 139, 115-126.	3.7	223
5	NETMORPH: A Framework for the Stochastic Generation of Large Scale Neuronal Networks With Realistic Neuron Morphologies. Neuroinformatics, 2009, 7, 195-210.	1.5	154
6	Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clinical, 2016, 11, 435-449.	1.4	137
7	Association of Cerebral Amyloid- β^2 Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
8	Different functional connectivity and network topology in behavioral variant of frontotemporal dementia and Alzheimer's disease: an EEG study. Neurobiology of Aging, 2016, 42, 150-162.	1.5	129
9	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- β^2 β^{42} Analysis Results. Clinical Chemistry, 2018, 64, 576-585.	1.5	126
10	Single-Subject Grey Matter Graphs in Alzheimer's Disease. PLoS ONE, 2013, 8, e58921.	1.1	107
11	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiology of Aging, 2017, 57, 133-142.	1.5	91
12	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
13	Disruption of structural and functional networks in long-standing multiple sclerosis. Human Brain Mapping, 2014, 35, 5946-5961.	1.9	79
14	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology, 2016, 279, 838-848.	3.6	79
15	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurology, 2017, 74, 1481.	4.5	77
16	Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease. Brain Connectivity, 2014, 4, 337-346.	0.8	69
17	Unbiased estimates of cerebrospinal fluid β^2 -amyloid β^{42} cutoffs in a large memory clinic population. Alzheimer's Research and Therapy, 2017, 9, 8.	3.0	60
18	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. Alzheimer's and Dementia, 2017, 13, 1226-1236.	0.4	59

#	ARTICLE	IF	CITATIONS
19	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. PLoS ONE, 2014, 9, e102995.	1.1	56
20	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. Neurobiology of Aging, 2018, 61, 75-81.	1.5	52
21	Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiology of Aging, 2016, 37, 154-160.	1.5	51
22	Sex differences in CSF biomarkers vary by Alzheimer disease stage and <i>APOE</i> ϵ 4 genotype. Neurology, 2020, 95, e2378-e2388.	1.5	48
23	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiology of Aging, 2018, 61, 198-206.	1.5	44
24	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 43-52.	1.2	42
25	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	2.4	42
26	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Human Brain Mapping, 2018, 39, 3143-3151.	1.9	40
27	Gray matter networks and cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 382-391.	1.4	39
28	Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. NeuroImage: Clinical, 2017, 15, 613-624.	1.4	38
29	Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs. Scientific Reports, 2017, 7, 9685.	1.6	38
30	Impact of <i>APOE</i> ϵ 4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiology of Aging, 2016, 38, 14-20.	1.5	37
31	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. Neurology, 2021, 96, e2673-e2684.	1.5	37
32	Grey matter networks in people at increased familial risk for schizophrenia. Schizophrenia Research, 2015, 168, 1-8.	1.1	33
33	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S299-305.	0.4	31
34	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 2018, 10, 67.	1.7	29
35	<i>APOE</i> ϵ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 65.	3.0	28
36	Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. Human Brain Mapping, 2016, 37, 1194-1208.	1.9	25

#	ARTICLE	IF	CITATIONS
37	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 73.	3.0	25
38	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. <i>Neurobiology of Aging</i> , 2018, 61, 238-244.	1.5	23
39	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1037-1047.	1.7	23
40	Survival in memory clinic cohort is short, even in young-onset dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 726-728.	0.9	22
41	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. <i>Journal of Psychiatric Research</i> , 2018, 104, 183-191.	1.5	21
42	Low normal cerebrospinal fluid A β 242 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , 2017, 81, 749-753.	2.8	20
43	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. <i>Lecture Notes in Computer Science</i> , 2016, , 87-96.	1.0	19
44	The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. <i>Brain Connectivity</i> , 2016, 6, 1-8.	0.8	18
45	Functional brain network centrality is related to APOE genotype in cognitively normal elderly. <i>Brain and Behavior</i> , 2018, 8, e01080.	1.0	18
46	The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 513-523.	1.8	17
47	Brain Amyloid Pathology and Cognitive Function. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2285.	3.8	15
48	Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1029-1039.	1.2	14
49	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , 2021, 3, fcab201.	1.5	14
50	Insights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis. <i>Scientific Data</i> , 2021, 8, 312.	2.4	12
51	Biomarker A+T β : is this Alzheimer's disease or not? A combined CSF and pathology study. <i>Brain</i> , 2023, 146, 1166-1174.	3.7	12
52	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa102.	1.5	11
53	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. <i>Neurology</i> , 2019, 92, e2699-e2705.	1.5	10
54	Single-subject structural cortical networks in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1392-1401.	1.4	10

#	ARTICLE	IF	CITATIONS
55	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. <i>Brain Communications</i> , 2020, 2, fcaa177.	1.5	10
56	Amyloid- β , cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.	1.7	9
57	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 50, 77-86.	1.5	6
58	Concatenating plasma p-tau to Alzheimer's disease. <i>Brain</i> , 2021, 144, 14-17.	3.7	6
59	Capturing the Alzheimer's disease pathological cascade. <i>Lancet Neurology</i> , The, 2018, 17, 199-200.	4.9	4
60	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. <i>Brain Communications</i> , 2022, 4, fcac026.	1.5	4
61	Chasing the start of sporadic Alzheimer's disease running in families. <i>Brain</i> , 2018, 141, 1589-1591.	3.7	2
62	Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid1-42. <i>Neurobiology of Aging</i> , 2021, 107, 42-52.	1.5	2
63	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. <i>Lecture Notes in Computer Science</i> , 2016, , 104-112.	1.0	2
64	O3-14-04: The relation between eeg spectral analysis and clinical progression in non-demented, amyloid-positive subjects. , 2015, 11, P255-P256.		1
65	P4-120: GREY MATTER CONNECTIVITY IS RELATED TO COGNITIVE IMPAIRMENT IN EARLY AND LATE ONSET AD. , 2014, 10, P828-P828.		0
66	P1-233: MULTIMODAL BRAIN NETWORK ALTERATIONS IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT PATIENTS. , 2014, 10, P389-P390.		0
67	P4-040: Use of recent research criteria for inclusion and use of biomarkers as endpoint in preclinical and prodromal Alzheimer's disease (AD) trials: An Alzheimer's disease neuroimaging initiative (ADNI) study. , 2015, 11, P780-P781.		0
68	O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression. , 2015, 11, P317-P317.		0
69	O3-08-01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. <i>Alzheimer's and Dementia</i> , 2016, 12, P303.	0.4	0
70	ICP-147: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology. <i>Alzheimer's and Dementia</i> , 2016, 12, P109.	0.4	0
71	O4-02-04: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology. <i>Alzheimer's and Dementia</i> , 2016, 12, P335.	0.4	0
72	[P1-392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P417.	0.4	0

#	ARTICLE	IF	CITATIONS
73	[P4â€“302]: DOES BRAIN AMYLOID DEPOSITION IMPACT EVERYDAY FUNCTIONING IN SUBJECTS WITH COGNITIVE COMPLAINTS? RESULTS FROM THE INSIGHT COHORT. Alzheimer's and Dementia, 2017, 13, P1406.	0.4	0
74	[ICâ€“Pâ€“036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P32.	0.4	0
75	[ICâ€“Pâ€“085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P69.	0.4	0
76	[ICâ€“Pâ€“110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P87.	0.4	0
77	[P1â€“440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P451.	0.4	0
78	[O1â€“05â€“03]: CSF AMYLOID BETA 1â€“42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€“DEPENDENT UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	0.4	0
79	[O3â€“06â€“04]: PROMINENT NONâ€“MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION. Alzheimer's and Dementia, 2017, 13, P912.	0.4	0